NeoGenomics (NEO) Reports In-Line Q1 EPS, Guides FY Revenue Below Estimates, FY EPS In-Line

NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $61.7 million versus the consensus estimate of $61.35 million.

GUIDANCE:

NeoGenomics sees FY2017 EPS of $0.17-$0.21, versus the consensus of $0.19. NeoGenomics sees FY2017 revenue of $255-265 million, versus the consensus of $264.6 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c